RadNet Q2 Revenue Jumps 25% to Record $622.7M, Lifts 2026 Guidance
RDNT sits 42% above its 52-week low of $50.76.
Summary
RadNet delivered a standout Q2 with revenue surging 25% to $622.7M and Adjusted EBITDA up 22.7% to $99.7M, both quarterly records. The Digital Health segment grew revenue 56.5% to $32.4M, with ARR nearly doubling to $105.5M, now 63% from external customers. Management raised full-year 2026 guidance for Imaging Center revenue, Adjusted EBITDA, and free cash flow, signaling confidence in sustained momentum. This follows the $250M term loan secured in June to fund growth, and the recent FDA clearance for DeepHealth's breast ultrasound AI, which will roll out across RadNet centers by year-end. A new joint venture with Trinity Health in Boise adds five centers and expands DeepHealth software adoption. The combination of accelerating organic volume, favorable mix shift to advanced imaging, and scaling AI solutions positions RadNet for continued outperformance.
At the time of this announcement, RDNT was trading at $72.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $50.76 to $85.84. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.